Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment

Lorenzo Pignataro, Elena Arisi, Giuseppe Sambataro, Massimiliano Marco Corsi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and Objectives: Fas and its specific ligand (Fas-L), both of which are involved in apoptosis, exist in membrane-bound and soluble forms. The soluble forms (sFas and sFas-L) have been observed in various tumours, but their clinical significance has not yet been clarified. The aim of this study was to assess serum sFas and sFas-L levels in patients with laryngeal squamous cell carcinoma (LSCC) and their possible correlations with surgical treatment. Methods: Serum sFas and sFas-L levels were determined by ELISA in samples taken from 26 LSCC patients on the day before surgery (T0), and 2 weeks (T1) and 6 months after surgery (T2), and in samples taken from 35 healthy volunteers. Results: The mean serum sFas levels in the 35 healthy volunteers and the 26 LSCC patients at T0 were respectively 5941 ± 411 pg/ml and 6290 ± 652 pg/ml (P = 0.63), and the mean serum sFas-L levels were 0.1 ± 0.05 ng/ml and 2.95 ± 0.8 ng/ml (P <0.0001). After surgery, there was a statistically significant decrease in sFas at both T1 (P <0.05) and T2 (P <0.01), and in sFas-L at T2 (P <0.01). Conclusions: The decrease in sFas and sFas-L levels after surgery suggest that they may be produced by or closely linked to tumour cells. Larger prospective clinical studies of patients with LSCC will be needed to establish the clinical significance of sFas and sFas-L, as reported for other neoplasms.

Original languageEnglish
Pages (from-to)112-115
Number of pages4
JournalJournal of Surgical Oncology
Volume83
Issue number2
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Fas Ligand Protein
Squamous Cell Carcinoma
Carcinoma
Serum
Healthy Volunteers
Neoplasms
Therapeutics
Ambulatory Surgical Procedures
Enzyme-Linked Immunosorbent Assay
Prospective Studies
Apoptosis
Ligands
Membranes

Keywords

  • Laryngeal carcinoma
  • Soluble Fas
  • Soluble Fas ligand
  • Surgical treatment

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment. / Pignataro, Lorenzo; Arisi, Elena; Sambataro, Giuseppe; Corsi, Massimiliano Marco.

In: Journal of Surgical Oncology, Vol. 83, No. 2, 01.06.2003, p. 112-115.

Research output: Contribution to journalArticle

@article{2aa6b5caac514575b5407582352c790c,
title = "Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment",
abstract = "Background and Objectives: Fas and its specific ligand (Fas-L), both of which are involved in apoptosis, exist in membrane-bound and soluble forms. The soluble forms (sFas and sFas-L) have been observed in various tumours, but their clinical significance has not yet been clarified. The aim of this study was to assess serum sFas and sFas-L levels in patients with laryngeal squamous cell carcinoma (LSCC) and their possible correlations with surgical treatment. Methods: Serum sFas and sFas-L levels were determined by ELISA in samples taken from 26 LSCC patients on the day before surgery (T0), and 2 weeks (T1) and 6 months after surgery (T2), and in samples taken from 35 healthy volunteers. Results: The mean serum sFas levels in the 35 healthy volunteers and the 26 LSCC patients at T0 were respectively 5941 ± 411 pg/ml and 6290 ± 652 pg/ml (P = 0.63), and the mean serum sFas-L levels were 0.1 ± 0.05 ng/ml and 2.95 ± 0.8 ng/ml (P <0.0001). After surgery, there was a statistically significant decrease in sFas at both T1 (P <0.05) and T2 (P <0.01), and in sFas-L at T2 (P <0.01). Conclusions: The decrease in sFas and sFas-L levels after surgery suggest that they may be produced by or closely linked to tumour cells. Larger prospective clinical studies of patients with LSCC will be needed to establish the clinical significance of sFas and sFas-L, as reported for other neoplasms.",
keywords = "Laryngeal carcinoma, Soluble Fas, Soluble Fas ligand, Surgical treatment",
author = "Lorenzo Pignataro and Elena Arisi and Giuseppe Sambataro and Corsi, {Massimiliano Marco}",
year = "2003",
month = "6",
day = "1",
doi = "10.1002/jso.10246",
language = "English",
volume = "83",
pages = "112--115",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment

AU - Pignataro, Lorenzo

AU - Arisi, Elena

AU - Sambataro, Giuseppe

AU - Corsi, Massimiliano Marco

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Background and Objectives: Fas and its specific ligand (Fas-L), both of which are involved in apoptosis, exist in membrane-bound and soluble forms. The soluble forms (sFas and sFas-L) have been observed in various tumours, but their clinical significance has not yet been clarified. The aim of this study was to assess serum sFas and sFas-L levels in patients with laryngeal squamous cell carcinoma (LSCC) and their possible correlations with surgical treatment. Methods: Serum sFas and sFas-L levels were determined by ELISA in samples taken from 26 LSCC patients on the day before surgery (T0), and 2 weeks (T1) and 6 months after surgery (T2), and in samples taken from 35 healthy volunteers. Results: The mean serum sFas levels in the 35 healthy volunteers and the 26 LSCC patients at T0 were respectively 5941 ± 411 pg/ml and 6290 ± 652 pg/ml (P = 0.63), and the mean serum sFas-L levels were 0.1 ± 0.05 ng/ml and 2.95 ± 0.8 ng/ml (P <0.0001). After surgery, there was a statistically significant decrease in sFas at both T1 (P <0.05) and T2 (P <0.01), and in sFas-L at T2 (P <0.01). Conclusions: The decrease in sFas and sFas-L levels after surgery suggest that they may be produced by or closely linked to tumour cells. Larger prospective clinical studies of patients with LSCC will be needed to establish the clinical significance of sFas and sFas-L, as reported for other neoplasms.

AB - Background and Objectives: Fas and its specific ligand (Fas-L), both of which are involved in apoptosis, exist in membrane-bound and soluble forms. The soluble forms (sFas and sFas-L) have been observed in various tumours, but their clinical significance has not yet been clarified. The aim of this study was to assess serum sFas and sFas-L levels in patients with laryngeal squamous cell carcinoma (LSCC) and their possible correlations with surgical treatment. Methods: Serum sFas and sFas-L levels were determined by ELISA in samples taken from 26 LSCC patients on the day before surgery (T0), and 2 weeks (T1) and 6 months after surgery (T2), and in samples taken from 35 healthy volunteers. Results: The mean serum sFas levels in the 35 healthy volunteers and the 26 LSCC patients at T0 were respectively 5941 ± 411 pg/ml and 6290 ± 652 pg/ml (P = 0.63), and the mean serum sFas-L levels were 0.1 ± 0.05 ng/ml and 2.95 ± 0.8 ng/ml (P <0.0001). After surgery, there was a statistically significant decrease in sFas at both T1 (P <0.05) and T2 (P <0.01), and in sFas-L at T2 (P <0.01). Conclusions: The decrease in sFas and sFas-L levels after surgery suggest that they may be produced by or closely linked to tumour cells. Larger prospective clinical studies of patients with LSCC will be needed to establish the clinical significance of sFas and sFas-L, as reported for other neoplasms.

KW - Laryngeal carcinoma

KW - Soluble Fas

KW - Soluble Fas ligand

KW - Surgical treatment

UR - http://www.scopus.com/inward/record.url?scp=0038548055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038548055&partnerID=8YFLogxK

U2 - 10.1002/jso.10246

DO - 10.1002/jso.10246

M3 - Article

C2 - 12772205

AN - SCOPUS:0038548055

VL - 83

SP - 112

EP - 115

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -